Treatment of gastropathy and gastric antral vascular ectasia in patients with portal hypertension

Current Treatment Options in Gastroenterology

Volumn 10, Issue 6, 2007, Pages 483-494

  Ripoll, Cristina ^b   Garcia Tsao, Guadalupe ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ALUMINUM HYDROXIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYCLOSPORIN; DIURETIC AGENT; ETHINYLESTRADIOL; INSULIN; IRON; NADOLOL; NONSTEROID ANTIINFLAMMATORY AGENT; NORETHISTERONE ACETATE; OCTREOTIDE; ORAL ANTIDIABETIC AGENT; PROPOFOL; PROPRANOLOL; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; TERLIPRESSIN; VASOACTIVE AGENT;

ACNE; ACUTE DISEASE; ARGON PLASMA COAGULATION; BLOOD PRESSURE; BLOOD TRANSFUSION; BRADYCARDIA; BREAST TENDERNESS; BRONCHOSPASM; CHRONIC DISEASE; CLINICAL TRIAL; CONTINUOUS INFUSION; COST EFFECTIVENESS ANALYSIS; CRYOTHERAPY; DIETARY INTAKE; DIFFERENTIAL DIAGNOSIS; DIZZINESS; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG SELECTIVITY; DRUG WITHDRAWAL; DYSMENORRHEA; DYSPNEA; ENDOSCOPIC THERAPY; FATIGUE; GALLSTONE; GASTRECTOMY BILLROTH I; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL SYMPTOM; HEART RATE; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOKALEMIA; HYPOTHYROIDISM; IRON DEFICIENCY ANEMIA; ISCHEMIA; LIFESTYLE MODIFICATION; LIVER CIRRHOSIS; LIVER DISEASE; MENORRHAGIA; MOOD DISORDER; NAUSEA; NEODYMIUM LASER; PALLOR; PORTAL HYPERTENSION; PORTOSYSTEMIC ANASTOMOSIS; REVIEW; SIDE EFFECT; SINUSITIS; STOMACH ANTRUM VASCULAR ECTASIA; STOMACH DISEASE; STOMACH MUCOSA; UPPER GASTROINTESTINAL BLEEDING; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; UTERINE CERVIX CYTOLOGY; VAGINA CANDIDIASIS; VAGINITIS; VOMITING; WEIGHT GAIN;

EID: 37349007885     PISSN: 10928472     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11938-007-0048-5     Document Type: Review

References (70)

1. Primignani M, Carpinelli L, Preatoni P, et al.: Natural history of portal hypertensive gastropathy in patients with liver cirrhosis. The New Italian Endoscopic Club for the study and treatment of esophageal varices (NIEC). Gastroenterology 2000, 119:181-187.
2. Hashizume M, Sugimachi K: Classification of gastric lesions associated with portal hypertension. J Gastroenterol Hepatol 1995, 10:339-343.
3. McCormack TT, Sims J, Eyre-Brook I, et al.: Gastric lesions in portal hypertension: inflammatory gastritis or congestive gastropathy? Gut 1985, 26:1226-1232.
4. Spina GP, Arcidiacono R, Bosch J, et al.: Gastric endoscopic features in portal hypertension: final report of a consensus conference, Milan, Italy, September 19, 1992. J Hepatol 1994, 21:461-467.
5. Tanoue K, Hashizume M, Wada H, et al.: Effects of endoscopic injection sclerotherapy on portal hypertensive gastropathy: a prospective study. Gastrointest Endosc 1992, 38:582-585.
6. D'Amico G, Montalbano L, Traina M, et al.: Natural history of congestive gastropathy in cirrhosis. The Liver Study Group of V. Cervello Hospital. Gastroenterology 1990, 99:1558-1564.
7. Sarin SK, Shahi HM, Jain M, et al.: The natural history of portal hypertensive gastropathy: influence of variceal eradication. Am J Gastroenterol 2000, 95:2888-2893.
8. Ito K, Shiraki K, Sakai T, et al.: Portal hypertensive colopathy in patients with liver cirrhosis. World J Gastroenterol 2005, 11:3127-3130.
9. Menchen L, Ripoll C, Marin-Jimenez I, et al.: Prevalence of portal hypertensive duodenopathy in cirrhosis: clinical and haemodynamic features. Eur J Gastroenterol Hepatol 2006, 18:649-653.
10. Misra SP, Dwivedi M, Misra V: Prevalence and factors influencing hemorrhoids, anorectal varices, and colopathy in patients with portal hypertension. Endoscopy 1996, 28:340-345.
11. Bresci G, Parisi G, Capria A: Clinical relevance of colonic lesions in cirrhotic patients with portal hypertension. Endoscopy 2006, 38:830-835.
12. Merli M, Nicolini G, Angeloni S, et al.: The natural history of portal hypertensive gastropathy in patients with liver cirrhosis and mild portal hypertension. Am J Gastroenterol 2004, 99:1959-1965.
13. Fontana RJ, Sanyal AJ, Mehta S, et al.: Portal hypertensive gastropathy in chronic hepatitis C patients with bridging fibrosis and compensated cirrhosis: results from the HALT-C trial. Am J Gastroenterol 2006, 101:983-992.
14. Sarin SK, Sreenivas DV, Lahoti D, Saraya A: Factors influencing development of portal hypertensive gastropathy in patients with portal hypertension. Gastroenterology 1992, 102:994-999.
15. Gupta R, Saraswat VA, Kumar M, et al.: Frequency and factors influencing portal hypertensive gastropathy and duodenopathy in cirrhotic portal hypertension. J Gastroenterol Hepatol 1996, 11:728-733.
16. de la Pena J, Rivero M, Sanchez E, et al.: Variceal ligation compared with endoscopic sclerotherapy for variceal hemorrhage: prospective randomized trial. Gastrointest Endosc 1999, 49:417-423.
17. Sarin SK, Govil A, Jain AK, et al.: Prospective randomized trial of endoscopic sclerotherapy versus variceal band ligation for esophageal varices: influence on gastropathy, gastric varices and variceal recurrence. J Hepatol 1997, 26:826-832.
18. Hou MC, Lin HC, Chen CH, et al.: Changes in portal hypertensive gastropathy after endoscopic variceal sclerotherapy or ligation: an endoscopic observation. Gastrointest Endosc 1995, 42:139-144.
19. Conn HO, Grace ND, Bosch J, et al.: Propranolol in the prevention of the first hemorrhage from esophagogastric varices: a multicenter, randomized clinical trial. The Boston-New Haven-Barcelona Portal Hypertension Study Group. Hepatology 1991, 13:902-912.
20. Hosking SW, Kennedy HJ, Seddon I, Triger DR: The role of propranolol in congestive gastropathy of portal hypertension. Hepatology 1987, 7:437-441.
21. Perez-Ayuso RM, Pique JM, Bosch J, et al.: Propranolol in prevention of recurrent bleeding from severe portal hypertensive gastropathy in cirrhosis. Lancet 1991, 337:1431-1434.
22. Lo GH, Lai KH, Cheng JS, et al.: The effects of endoscopic variccal ligation and propranolol on portal hypertensive gastropathy: a prospective, controlled trial. Gastrointest Endosc 2001, 53:579-584.
23. Zhou Y, Qiao L, Wu J, et al.: Comparison of the efficacy of octreotide, vasopressin, and omeprazole in the control of acute bleeding in patients with portal hypertensive gastropathy: a controlled study. J Gastroenterol Hepatol 2002, 17:973-979.
24. Kouroumalis EA, Koutroubakis IE, Manousos ON: Somatostatin for acute severe bleeding from portal hypertensive gastropathy. Eur J Gastroenterol Hepatol 1998, 10:509-512.
25. Bruha R, Marecek Z, Spicak J, et al.: Double-blind randomized, comparative multicenter study of the effect of terlipressin in the treatment of acute esophageal variceal and/or hypertensive gastropathy bleeding. Hepatogastroenterology 2002, 49:1161-1166.
26. Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W: Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Am J Gastroenterol 2007, 102:2086-2102.
27. Wagatsuma Y, Naritaka Y, Shimakawa T, et al.: Clinical usefulness of the angiotensin II receptor antagonist losartan in patients with portal hypertensive gastropathy. Hepatogastroenterology 2006, 53:171-174.
28. Karajeh MA, Hurlstone DP, Stephenson TJ, et al.: Refractory bleeding from portal hypertensive gastropathy: a further novel role for thalidomide therapy? Eur J Gastroenterol Hepatol 2006, 18:545-548.
29. Cremers MI, Oliveira AP, Alves AL, Freitas J: Portal hypertensive gastropathy: treatment with corticosteroids. Endoscopy 2002, 34:177.
30. Orloff MJ, Orloff MS, Orloff SL, Haynes KS: Treatment of bleeding from portal hypertensive gastropathy by portacaval shunt. Hepatology 1995, 21:1011-1017.
31. Urata J, Yamashita Y, Tsuchigame T, et al.: The effects of transjugular intrahepatic portosystemic shunt on portal hypertensive gastropathy. J Gastroenterol Hepatol 1998, 13:1061-1067.
32. Soin AS, Acharya SK, Mathur M, et al.: Portal hypertensive gastropathy in noncirrhotic patients. The effect of lienorenal shunts. J Clin Gastroenterol 1998, 26:64-67. Discussion 68.
33. Mezawa S, Homma H, Ohta H, et al.: Effect of transjugular intrahepatic portosystemic shunt formation on portal hypertensive gastropathy and gastric circulation. Am J Gastroenterol 2001, 96:1155-1159.
34. Kamath PS, Lacerda M, Ahlquist DA, et al.: Gastric mucosal responses to intrahepatic portosystemic shunting in patients with cirrhosis. Gastroenterology 2000, 118:905-911.
35. Vincent C, Pomier-Layrargues G, Dagenais M, et al.: Cure of gastric antral vascular ectasia by liver transplantation despite persistent portal hypertension: a clue for pathogenesis. Liver Transpl 2002, 8:717-720.
36. Spahr L, Villeneuve JP, Dufresne MP, et al.: Gastric antral vascular ectasia in cirrhotic patients: absence of relation with portal hypertension. Gut 1999, 44:739-742.
37. Suit PF, Petras RE, Bauer TW, Petrini JL, Jr: Gastric antral vascular ectasia. A histologic and morphometric study of "the watermelon stomach." Am J Surg Pathol 1987, 11:750-757.
38. Dulai GS, Jensen DM, Kovacs TO, et al.: Endoscopic treatment outcomes in watermelon stomach patients with and without portal hypertension. Endoscopy 2004, 36:68-72.
39. Sato T, Yamazaki K, Toyota J, et al.: Efficacy of argon plasma coagulation for gastric antral vascular ectasia associated with chronic liver disease. Hepatol Res 2005, 32:121-126.
40. Yusoff I, Brennan F, Ormonde D, Laurence B: Argon plasma coagulation for treatment of watermelon stomach. Endoscopy 2002, 34:407-410.
41. Sebastian S, McLoughlin R, Qasim A, et al.: Endoscopic argon plasma coagulation for the treatment of gastric antral vascular ectasia (watermelon stomach): long-term results. Dig Liver Dis 2004, 36:212-217.
42. Roman S, Saurin JC, Dumortier J, et al.: Tolerance and efficacy of argon plasma coagulation for controlling bleeding in patients with typical and atypical manifestations of watermelon stomach. Endoscopy 2003, 35:1024-1028.
43. Kwan V, Bourke MJ, Williams SJ, et al.: Argon plasma coagulation in the management of symptomatic gastrointestinal vascular lesions: experience in 100 consecutive patients with long-term follow-up. Am J Gastroenterol 2006, 101:58-63.
44. Labenz J, Borsch G: Bleeding watermelon stomach treated by Nd-YAG laser photocoagulation. Endoscopy 1993, 25:240-242.
45. Mathou NG, Lovat LB, Thorpe SM, Bown SG. Nd: YAG laser induces long-term remission in transfusion-dependent patients with watermelon stomach. Lasers Med Sci 2004, 18:213-218.
46. Selinger RR, McDonald GB, Hockenbery DM, et al.: Efficacy of neodymium:YAG laser therapy for gastric antral vascular ectasia (GAVE) following hematopoietic cell transplant. Bone Marrow Transplant 2006, 37:191-197.
47. Kantsevoy SV, Cruz-Correa MR, Vaughn CA, et al.: Endoscopic cryotherapy for the treatment of bleeding mucosal vascular lesions of the GI tract: a pilot study. Gastrointest Endosc 2003, 57:403-406.
48. Cho S, Yong E, Zanati S, et al.: Endoscopic cryotherapy for the management of gastric antral vascular ectasia (GAVE): a pilot study [abstract]. Gastrointest Endosc 2006, 63:AB81.
49. Tran A, Villeneuve JP, Bilodeau M, et al.: Treatment of chronic bleeding from gastric antral vascular ectasia (GAVE) with estrogen-progesterone in cirrhotic patients: an open pilot study. Am J Gastroenterol 1999, 94:2909-2911.
50. McCormick PA, Ooi H, Crosbie O: Tranexamic acid for severe bleeding gastric antral vascular ectasia in cirrhosis. Gut 1998, 42:750-752.
51. Park RH, Danesh BJ, Upadhyay R, et al.: Gastric antral vascular ectasia (watermelon stomach) - therapeutic options. Postgrad Med J 1990, 66:720-723.
52. Dunne KA, Hill J, Dillon JF: Treatment of chronic transfusion-dependent gastric antral vascular ectasia (watermelon stomach) with thalidomide. Eur J Gastroenterol Hepatol 2006, 18:455-456.
53. Caletti GC, Brocchi E, Ferrari A, et al.: Value of endoscopic ultrasonography in the management of portal hypertension. Endoscopy 1992, 24(Suppl 1):342-346.
54. Nardone G, Rocco A, Balzano T, Budillon G: The efficacy of octreotide therapy in chronic bleeding due to vascular abnormalities of the gastrointestinal tract. Aliment Pharmacol Ther 1999, 13:1429-1436.
55. Mann NS, Rachut E: Gastric antral vascular ectasia causing severe hypoalbuminemia and anemia cured by antrectomy. J Clin Gastroenterol 2002, 34:284-286.
56. Pljesa S, Golubovic G, Tomasevic R, et al.: "Watermelon stomah" in patients on chronic hemodialysis. Ren Fail 2005, 27:643-646.
57. Jabbari M, Cherry R, Lough JO, et al.: Gastric antral vascular ectasia: the watermelon stomach. Gastroenterology 1984, 87:1165-1170.
58. Ward EM, Raimondo M, Rosser BG, et al.: Prevalence and natural history of gastric antral vascular ectasia in patients undergoing orthotopic liver transplantation. J Clin Gastroenterol 2004, 38:898-900.
59. Cirera I, Feu F, Luca A, et al.: Effects of bolus injections and continuous infusions of somatostatin and placebo in patients with cirrhosis: a double-blind hemodynamic investigation. Hepatology 1995, 22:106-111.
60. Escorsell A, Bandi JC, Andreu V, et al.: Desensitization to the effects of intravenous octreotide in cirrhotic patients with portal hypertension. Gastroenterology 2001, 120:161-169.
61. Baik SK, Jeong PH, Ji SW, et al.: Acute hemodynamic effects of octreotide and terlipressin in patients with cirrhosis: a randomized comparison. Am J Gastroenterol 2005, 100:631-635.
62. Spahr L, Giostra E, Frossard JL, et al.: A 3-month course of long-acting repeatable octreotide (sandostatin LAR) improves portal hypertension in patients with cirrhosis: a randomized controlled study. Am J Gastroenterol 2007, 102:1397-1405.
63. Villanueva C, Planella M, Aracil C, et al.: Hemodynamic effects of terlipressin and high somatostatin dose during acute variceal bleeding in nonresponders to the usual somatostatin dose. Am J Gastroenterol 2005, 100:624-630.
64. Escorsell A, Bandi JC, Moitinho E, et al.: Time profile of the haemodynamic effects of terlipressin in portal hypertension. J Hepatol 1997, 26:621-627.
65. Bolognesi M, Balducci G, Garcia-Tsao G, et al.: Complications in the medical treatment of portal hypertension. In Portal Hypertension III. Oxford: Blackwell Science; 2001:180-203.
66. Angermayr B, Cejna M, Koenig F, et al.: Survival in patients undergoing transjugular intrahepatic portosystemic shunt: ePTFE-covered stentgrafts versus bare stents. Hepatology 2003, 38:1043-1050.
67. Boyer TD, Haskal ZJ: American Association for the Study of Liver Diseases Practice Guidelines: the role of transjugular intrahepatic portosystemic shunt creation in the management of portal hypertension. J Vasc Interv Radiol 2005, 16:615-629.
68. Banares R, Nunez O, Escudero M, et al.: Patients with cirrhosis and bare-stent TIPS may have increased risk of hepatocellular carcinoma. Hepatology 2005, 41:566-571.
69. Bureau C, Garcia-Pagan JC, Otal P, et al.: Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study. Gastroenterology 2004, 126:469-475.
70. Wahab PJ, Mulder CJ, den Hartog G, Thies JE: Argon plasma coagulation in flexible gastrointestinal endoscopy: pilot experiences. Endoscopy 1997, 29:176-181.